Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone.
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.
Receptos to deliver scientific presentation at Digestive Disease Week 2012 about the therapeutic role of RPC1063 in inflammatory bowel disease
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
DNA strand breakage by peroxidase-activated mitoxantrone.
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Current and future immunotherapy targets in autoimmune neurology.
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial.
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers.
Comprehensive Immunophenotyping of CSF cells in relapsing-remitting multiple sclerosis patients with daclizumb therapy
Product Portfolio, Meda
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
LKB1/STRAD promotes axon initiation during neuronal polarization.
AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of masitinib in the treatment of pancreatic cancer
Testicular hypofunction and multiple sclerosis risk: a record-linkage study.
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
Ampyra (dalfampridine)
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
Multiple Sclerosis.

Pages